ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
Sugar stocks rally continues: Balrampur Chini, Dhampur Sugar, Uttam Sugar Mills rally up to 4%. Two big triggers
Sugar stocks rallied as domestic sugar prices surged sharply over the past month. Government data showed retail prices rising from Rs 48.18/kg on July 20